产品
编 号：F742569
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1116433-11-4
产品详情
生物活性：
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
体内研究：
Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD).Animal Model:Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)
Dosage:60 μg or 300μg
Administration:Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result:Decreased mortality compared to the vehicle (100% vs. 10%).
体外研究：
Itolizumab (100 μg/mL) inhibits T cell proliferation.Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs.Itolizumab (40 μg/mL) reduces CD26hiCD161+?CD8+?T cells during culture of PBMCs overnight.Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions.
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
体内研究：
Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD).Animal Model:Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)
Dosage:60 μg or 300μg
Administration:Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result:Decreased mortality compared to the vehicle (100% vs. 10%).
体外研究：
Itolizumab (100 μg/mL) inhibits T cell proliferation.Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs.Itolizumab (40 μg/mL) reduces CD26hiCD161+?CD8+?T cells during culture of PBMCs overnight.Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备